[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636345":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":39,"locations":45,"responsibleParty":66,"collaborators":69,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":12,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":12,"enrollmentInfo":80,"targetDuration":12,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":48,"whyStopped":12,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Minia University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Hydration","NO_INTERVENTION","o Standard preventive measures for cisplatin nephrotoxicity (e.g., pre and post hydration, antiemetics, magnesium and potassium supplementation as per unit protocol) will be applied.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Alpha Lipoic Acid + Standard Hydration","EXPERIMENTAL","* Patients will receive the same cisplatin based chemotherapy regimens and standard preventive measures as the control group.\n* In addition, they will receive oral alpha lipoic acid at a dose of \\[e.g., 600 mg\\] twice daily (ALA \\[brand\u002Fformulation\\], \\[manufacturer, country\\]) starting \\[e.g., 2 days\\] before the first cisplatin dose and continued throughout each chemotherapy cycle until 2 days after the last cisplatin administration in that cycle, for a total of 4 cycles",[18],"Drug: Alpha-Lipoic Acid (ALA)",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Alpha-Lipoic Acid (ALA)","The intervention under investigation is the administration of oral Alpha-Lipoic Acid (ALA) as an adjunct to standard cisplatin-based chemotherapy.",[14],[26,30,34,36],{"name":27,"affiliation":28,"role":29},"Ahmed Mostafa Abd-Elaziz","Department of Clinical Oncology, Faculty of Medicine, Minia University","STUDY_DIRECTOR",{"name":31,"affiliation":32,"role":33},"Amal Kamal Hussein","Faculty of Pharmacy, Minia University","STUDY_CHAIR",{"name":35,"affiliation":32,"role":29},"Eman Mohamed Sadek",{"name":37,"affiliation":32,"role":38},"Asmaa Basem Mohammed","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":12,"email":44},"Asmaa Mohammed","CONTACT","00201090824147","asmaa.bashandy@mu.edu.eg",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Minia University Hospital","RECRUITING","Minya","Minya Governorate","61111","Egypt","EG",{"type":55,"coordinates":56},"Point",[57,58],30.75813,28.09193,{"lat":58,"lon":57},[61,64,65],{"name":27,"role":42,"phone":62,"phoneExt":12,"email":63},"+20 10 09144024","dr_ahmad2012@yahoo.com",{"name":12,"role":42,"phone":12,"phoneExt":12,"email":44},{"name":37,"role":38,"phone":12,"phoneExt":12,"email":12},{"type":38,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Asmaa Bassem Mohammed","Teaching and Research Assistant",[70],{"name":47,"class":6},"100636345","phase-2-alpha-lipoic-acid-in-mitigating-cisplatin-induced-nephrotoxicity-100636345",false,"NCT07564479","Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity","Evaluation of Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity in Oncology Patients","Inclusion Criteria:\n\n* Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg\u002Fm2 per cycle (21-28 days each or fractionated).\n\nEastern Cooperative Oncology Group (ECOG) performance status 0-2. Baseline serum creatinine within normal range or estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73 m2.\n\nAbility to provide informed consent.\n\nExclusion Criteria:\n\n* Pre existing renal impairment (eGFR \\\u003C 60〖\" mL\u002Fmin\u002F1.73 m\" 〗\\^2or serum creatinine \\> 1.5 × upper limit of normal).\n\nConcomitant use of known nephrotoxic drugs that cannot be stopped (e.g., aminoglycosides, amphotericin B, high dose NSAIDs).\n\nUncontrolled hypertension, decompensated heart failure, or severe hepatic impairment.\n\nKnown allergy or intolerance to ALA. Pregnancy or lactation. Participation in another interventional clinical trial.","ALL","18 Years",{"count":81,"type":82},50,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes",[88,89],"Cisplatin Nephrotoxicity","Nephrotoxicity",[91,89,92,93],"Cisplatin","ALA","Alpha-Lipoic Acid","2026-04-26",{"date":96,"type":97},"2026-05-04","ACTUAL",{"date":99,"type":97},"2026-03-10",{"date":101,"type":82},"2027-06",{"name":5,"class":6},1]